Fol­low­ing AS­CO pre­view flop, Syn­dax bets on new com­bo deal with Nek­tar

San Fran’s I/O dar­ling Nek­tar Ther­a­peu­tics $NK­TR is hand­ing off ac­cess to its pop­u­lar can­cer can­di­date NK­TR-214 to see how the ther­a­py fairs when paired …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.